Kabra Drugs Limited Press Release Apr 13 2025

Subject: Certificate under Regulation (74(5) of the SEBI (Depositories and Participants) Regulations,2018 for the quarter ended March 31,2025. Reference: Kabra Drugs Limited (524322). In compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, we are forwarding herewith a copy of the Certificate dated April 1, 2025 received from Skyline Financial Services Pri